PP
AMGN icon

Paladin Partners’s Amgen AMGN Stock Holding History

Paladin Partners’s Portfolio AMGN Stock Details AMGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$784K Hold
1,860
– – 0.48% 28
2026
Q2 		$674K Hold
1,860
– – 0.45% 27
2026
Q1 		$654K Buy
1,860
+50
+3% +$17.8K 0.47% 29
2025
Q4 		$592K Buy
+1,810
New +$574K 0.44% 28

Other funds holding AMGN

FWCM
Ferguson Wellman Capital Management Portland, Oregon $8.38B AUM 25.07% 1-Year Est. Return
MSV
MN Services Vermogensbeheer The Hague, Netherlands $13.4B AUM 37.34% 1-Year Est. Return
ACM
Argent Capital Management St Louis, Missouri $3.14B AUM 31.36% 1-Year Est. Return
CA
CapWealth Advisors Franklin, Tennessee $1.32B AUM 21.6% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $15.4B AUM 30.35% 1-Year Est. Return
GI
Gradient Investments Arden Hills, Minnesota $7B AUM 14.85% 1-Year Est. Return
YIA
YHB Investment Advisors West Hartford, Connecticut $1.59B AUM 21.04% 1-Year Est. Return
TF
Tompkins Financial Ithaca, New York $1.42B AUM 19.14% 1-Year Est. Return
VVP
Venture Visionary Partners Sylvania, Ohio $3.82B AUM 21.33% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

Paladin Partners's AMGN Position: Q3 2026 in Review

Paladin Partners held its Amgen (AMGN) position steady in Q3 2026 at 1,860 shares worth $784K. The position accounts for 0.48% of the portfolio, ranked #28.

Paladin Partners first reported a position in AMGN in Q4 2025 and has held it in 4 quarters since. 112 funds tracked by Wall St. Rank hold AMGN as of Q3 2026.

  • Paladin Partners held 1,860 shares of Amgen worth $784K as of Q3 2026.
  • Paladin Partners left its Amgen share count unchanged in Q3 2026.
  • Amgen made up 0.48% of Paladin Partners's portfolio in Q3 2026, its #28 holding.
  • Paladin Partners first reported a position in Amgen in Q4 2025 and has held it in 4 quarters since.
  • 112 funds tracked by Wall St. Rank held Amgen as of Q3 2026.

Based on Paladin Partners's 13F filing for Q3 2026, filed 6 Oct 2026.